We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sen. Richard Durbin (D-Ill.) has received assurance from Senate GOP leadership that there will be action this year on his amendment requiring manufacturers who sell dietary supplements containing stimulants to turn over to the FDA reports of serious adverse events (AEs).
The AARP has said it will endorse the drug importation bill sponsored by Sen. Byron Dorgan (D-N.D.) in large part because it contains a provision that would prevent pharmaceutical companies from choking off the supply of drugs manufactured in the U.S. to providers abroad.
The House passed sweeping legislation yesterday that would provide tax relief to all U.S. corporations, including drug manufacturers, that do business abroad.
Legislation sponsored by Sen. Judd Gregg (R-N.H.) to legalize drug imports from Canada and the European Union includes provisions that would establish federal licensing requirements and penalties for internet pharmacies.
The chairman of the Senate Health, Education, Labor and Pensions Committee is expected to introduce a bill that would impose a user fee on certain elements of the drug distribution channel to help pay for the resources needed to set up a system to safely import Rx drugs from Canada.
The holding company for one of the country’s largest tobacco companies has come out in support of a bill introduced by a bipartisan group of powerful Washington lawmakers that would require the FDA to regulate tobacco products.
With at least three serious drug importation bills pending in the Senate, a bipartisan group of lawmakers want Senate Majority Leader Bill Frist (R-Tenn.) to schedule a vote on the practice within the next five weeks.
A bill introduced by a bipartisan group of powerful Washington lawmakers that would require the FDA to regulate tobacco products has drawn support from an unlikely quarter — the holding company for one of the country’s largest tobacco companies.
The political firestorm ignited by the FDA’s decision not to approve OTC status for an emergency oral contraceptive earlier this month could intensify today with the expected introduction of a House bill directing the agency to conduct a formal review of the process it used to make its decision.
It appears unlikely that the current research and development (R&D) tax credit for corporations will be extended by Congress before it expires June 30, despite intense lobbying by business interests, including pharmaceutical company representatives, according to knowledgeable sources.